This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Orthofix JuniOrtho Plating System Gets Regulatory Clearances
by Zacks Equity Research
Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.
Amedisys Rides on Coronavirus-Led Business Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.
Quest Diagnostics Gets EUA for Coronavirus Sample Pool Testing
by Zacks Equity Research
Quest Diagnostics (DGX) is riding high on a slew of EUAs for the expanded use of its self-collection molecular diagnostic kit on different platforms.
Rising Coronavirus Cases Spark Lockdown Fears: 5 Defensive Picks
by Zacks Equity Research
Given the current coronavirus scenario, investors can invest in defensive stocks that can return well even during phases of market volatility
Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.
Integra Reports Organic Sales Drop in Preliminary Q2 Results
by Zacks Equity Research
Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.
Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center
by Zacks Equity Research
Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that display a bullish run. Stocks seeing price strength have a high chance of carrying the momentum forward.
Henry Schein Banks on Dental Consumable Amid Coronavirus Woes
by Zacks Equity Research
Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.
Henry Schein Medical to Expand in Telemedicine With VisualDx
by Zacks Equity Research
Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.
QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results
by Zacks Equity Research
Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.
Hologic Expands Product Portfolio With New Ultrasound System
by Zacks Equity Research
Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
by Zacks Equity Research
Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.
Medtronic Launches User-Friendly Insulin Infusion Set in US
by Zacks Equity Research
Medtronic's (MDT) MiniMed Mio Advance infusion set, is aimed at providing optimal user experience to insulin pump-using diabetic patients.
LabCorp Launches At-Home Coronavirus Test Collection Kit
by Zacks Equity Research
LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.
Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge
by Zacks Equity Research
Myriad Genetics (MYGN) collaborates with OptraHEALTH to provide an AI-powered cognitive ChatBOT to serve as a genetic health knowledge platform to prospective hereditary cancer patients.
Align Technology's Rollouts Aid Amid Procedural Deferrals
by Zacks Equity Research
Align Technology's (ALGN) new virtual solutions ensure continuity of care amid pandemic.
Thermo Fisher Stock Rises on Solid Q2 Growth Expectation
by Zacks Equity Research
Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
by Zacks Equity Research
IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.
Boston Scientific's (BSX) ICM System Receives FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.
3 MedTech Stocks to Buy Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Let's keep a watch on three stocks that have shown tremendous promise amid the pandemic.
Myriad Genetics Unveils New Home DNA Sample Collection Kit
by Zacks Equity Research
Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.